Latest news with #JasperTherapeutics
Yahoo
5 days ago
- Business
- Yahoo
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended June 30, 2025 and provided a corporate update. 'The compelling results we are generating in both CSU and CIndU continue to reinforce our belief that briquilimab has the potential to be a highly differentiated therapy in mast cell-driven diseases,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'We continue to generate strong data, with briquilimab driving complete responses in 89% of patients across the 240 mg and 360 mg single-dose cohorts in the BEACON study in CSU, 73% of CSU patients at 12 weeks in the open-label extension dosed at 180mg Q8W, and 92% of CIndU patients in the 180mg SPOTLIGHT cohort. With the favorable safety and tolerability profile we continue to observe, we believe briquilimab has the potential to be an important treatment option in chronic urticarias, and we remain well-positioned to deliver multiple catalysts over the coming quarters, which we believe can drive meaningful benefits for patients and long-term value for stockholders.' 'Our investigation into the 240mg Q8W and the 240mg/180mg Q8W cohorts of the BEACON study, which did not demonstrate the rapid onset and deep symptom control at levels we have observed in previous cohorts at varying dose levels, remains ongoing,' said Daniel Adelman, M.D., Interim Chief Medical Officer of Jasper. 'We are pursuing a number of avenues of investigation and expect to provide an update on the status of the investigation later this year. Meanwhile, the lack of any observed dose-limiting safety signals in these two cohorts enables us to also proceed with redosing those patients with drug product from a different lot, as well as enrolling an additional 10-12 new patients across those cohorts. We plan to report data from both the new patients added and the redosed patients in late 2025.' Highlights for Second Quarter 2025 and Recent Weeks Presented updated data from the BEACON Phase 1b/2a of subcutaneous briquilimab in adult participants with CSU, as well as from CSU patients in the related open-label extension study, both of which demonstrated robust efficacy: 89% (8 of 9) of participants in the 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0) following a single dose, with 7 of those patients achieving an initial clinical response by week 2. 73% (8 of 11) patients in the open-label extension study at 180 mg Q8W maintained a complete response at 12 weeks, and 82% of patients (9 of 11) demonstrated well-controlled disease at 12 weeks. Data from an additional 10-12 new patients being enrolled across the 240mg Q8W and the 240mg/180mg Q8W BEACON cohorts as well as additional data from the open-label extension study are anticipated later this year. Briquilimab continued to be well-tolerated with no dose limiting toxicities observed, and any safety observations potentially related to KIT blockade were infrequent and generally limited to low grade events, none of which resulted in discontinuations or dose delays and the majority of which resolved during repeat dosing. Commenced an investigation to identify the root cause of an atypical absence of UAS7 reduction in 11 of the 13 patients enrolled in the 240mg Q8W and 240mg/180mg Q8W cohorts of the BEACON study. Among other factors being examined, Jasper is assessing potential product lot variability in one lot of drug product first introduced into the BEACON study in those two cohorts, as all 10 patients dosed with drug supply from that lot failed to show reductions in their reported UAS7 scores. Jasper expects to complete the investigation in the second half of 2025, and in the near-term has provided new clinical drug supply from a different lot for ongoing dosing of existing patients, and is enrolling an additional 10-12 new patients in aggregate across those two cohorts. Jasper expects that the additional data on these cohorts, expected to be reported in late 2025, should be adequate to complete dose selection for the planned Phase 2b CSU study, which is now expected to commence mid-2026. Presented data from the 180mg cohort in the SPOTLIGHT study demonstrating 92% (11 of 12) complete response rate, 100% (12 of 12) clinical response, no serious or grade or higher adverse events, and a rapid onset of action with responses observed as early as one week-post treatment. Implemented a corporate restructuring, including a workforce reduction of approximately 50%, to focus resources on its urticaria programs and preserve capital. As part of the reorganization, Dr. Edwin Tucker stepped down as Chief Medical Officer effective August 1, 2025. He was succeeded in an interim capacity by Dr. Adelman, a member of Jasper's scientific advisory board and an industry veteran with a strong track record of advancing therapies for allergy and immunology indications. Halted its non-mast cell focused clinical and preclinical programs, including ongoing investigator sponsored trials and the SCID clinical program, to concentrate fully on briquilimab development in mast-cell driven diseases such as CSU and CIndU. Jasper also halted enrollment in the ETESIAN study in asthma and expects to report data from that study, as well as determine next steps in asthma, once the investigation into the anomalous BEACON cohorts is completed, which is expected to be in the second half of 2025. Second Quarter Fiscal 2025 Financial Results Cash and cash equivalents as of June 30, 2025, totaled $39.5 million. Research and development expense for the three months ended June 30, 2025, was $21.2 million. General and administrative expense for the three months ended June 30, 2025, was $5.9 million. Jasper reported a net loss of $26.7 million, or basic and diluted net loss per share attributable to common stockholders of $1.74 for the three months ended June 30, 2025. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU, and asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in both CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU and CIndU, its potential to be a highly differentiated therapy in mast cell-driven diseases, its potential to be an important treatment option in chronic urticarias; Jasper's ability to deliver multiple catalysts over the coming quarters, and the possibility such catalysts may drive meaningful benefits for patients and long term value for stockholders; Jasper's focus of its resources on the development of briquilimab in mast-cell driven diseases such as CSU and CIndU, including halting its other clinical and preclinical programs; the expected timing of announcing additional data from the BEACON and ETESIAN studies; the expected timing for initiating the planned Phase 2b CSU study; and the expected timing for completing the investigation regarding an atypical lack of UAS7 reduction in certain cohorts and for providing an update on such investigation. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper's investigation into the drug product lot may be inconclusive or may not lead to the anticipated conclusion; the risk that Jasper may be unable to raise capital to continue its operations and continue the BEACON study; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@ Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@ Molly Devlin (media) Real Chemistry 443-416-6675 mdevlin@ JASPER THERAPEUTICS, CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(in thousands, except share and per share data)(unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses Research and development(1) $ 21,196 $ 11,296 $ 37,353 $ 21,594 General and administrative(1) 5,880 4,697 11,525 9,471 Total operating expenses 27,076 15,993 48,878 31,065 Loss from operations (27,076 ) (15,993 ) (48,878 ) (31,065 ) Interest income 437 1,450 1,061 2,836 Other expense, net (84 ) (40 ) (147 ) (82 ) Total other income, net 353 1,410 914 2,754 Net loss and comprehensive loss $ (26,723 ) $ (14,583 ) $ (47,964 ) $ (28,311 ) Net loss per share attributable to common stockholders, basic and diluted $ (1.74 ) $ (0.97 ) $ (3.16 ) $ (2.00 ) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 15,333,962 14,986,367 15,178,904 14,160,634 (1) Amounts include non-cash stock based compensation expense as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Research and development $ 1,274 $ 1,009 $ 2,514 $ 1,829 General and administrative 543 473 1,114 822 Total $ 1,817 $ 1,482 $ 3,628 $ 2,651 JASPER THERAPEUTICS, CONSOLIDATED BALANCE SHEETS Assets June 30,2025 December 31,2024 Current assets: Cash and cash equivalents $ 39,510 $ 71,637 Prepaid expenses and other current assets 3,456 4,174 Total current assets 42,966 75,811 Property and equipment, net 1,331 1,875 Operating lease right-of-use assets 1,560 976 Restricted cash 417 417 Other non-current assets 192 820 Total assets $ 46,466 $ 79,899 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 8,034 $ 4,027 Current portion of operating lease liabilities 1,954 1,089 Accrued expenses and other current liabilities 10,512 10,121 Total current liabilities 20,500 15,237 Non-current portion of operating lease liabilities 201 724 Other non-current liabilities 2,264 2,264 Total liabilities 22,965 18,225 Commitments and contingencies — — Stockholders' equity: Preferred stock — — Common stock 2 2 Additional paid-in capital 312,332 302,541 Accumulated deficit (288,833 ) (240,869 ) Total stockholders' equity 23,501 61,674 Total liabilities and stockholders' equity $ 46,466 $ 79,899 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
12-07-2025
- Business
- Business Insider
BTIG Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)
In a report released today, Justin Zelin from BTIG maintained a Buy rating on Jasper Therapeutics, with a price target of $20.00. The company's shares opened today at $3.56. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Zelin covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Verastem, and Kura Oncology. According to TipRanks, Zelin has an average return of 2.6% and a 33.33% success rate on recommended stocks. In addition to BTIG, Jasper Therapeutics also received a Buy from H.C. Wainwright's Emily Bodnar in a report issued on July 9. However, on July 8, William Blair downgraded Jasper Therapeutics (NASDAQ: JSPR) to a Hold. The company has a one-year high of $26.05 and a one-year low of $2.27. Currently, Jasper Therapeutics has an average volume of 597.7K.
Yahoo
11-07-2025
- Business
- Yahoo
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief Medical Officer REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced a corporate reorganization to extend its cash runway, including a workforce reduction of approximately 50%. As part of the reorganization, Edwin Tucker, M.D., is departing as Jasper's Chief Medical Officer, and Daniel Adelman, M.D., a member of Jasper's Scientific Advisory Board, will assume the role of Acting Chief Medical Officer. In order to focus resources on the development of briquilimab in chronic urticaria, Jasper is halting its other clinical and preclinical programs. 'While we are taking steps to significantly streamline our operations, we remain committed to the development of briquilimab in chronic urticaria, where we have seen rapid, deep and durable responses along with a favorable safety profile in both CSU and CIndU,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'We look forward to sharing additional data from the BEACON and open label extension studies later this year. While it is very difficult to part with so many talented and valued members of our team, we view this as a necessary step to ensure we closely manage our capital to execute on our mission to deliver a differentiated therapeutics option to patients in need. I'd like to thank those leaving Jasper for their important contributions to the company, and in particular, I'd like to thank Dr. Tucker for his leadership as we advanced briquilimab into multiple clinical studies in mast cell diseases.' Corporate Updates and Revised Guidance Jasper has refined its operating plan to focus on its briquilimab programs in chronic urticaria, and as a result has executed a workforce reduction of approximately 50% of its current employees. In order to focus on developing briquilimab in chronic urticaria and completing the BEACON, SPOTLIGHT and open label extension studies, Jasper is halting its other clinical and preclinical programs, including the ETESIAN study in asthma, the SCID study and the ongoing investigator-sponsored studies. Jasper no longer plans to initiate additional mast cell focused clinical development program this year. Dr. Edwin Tucker is departing his role as Chief Medical Officer effective August 1, 2025. Dr. Daniel Adelman, an experienced clinical development executive and member of Jasper's scientific advisory board, will assume the role of Acting Chief Medical Officer as of that date. Dr. Adelman has held several leadership roles within the biopharma industry throughout his career, including Chief Medical Officer at Aimmune Therapeutics, Alvine Pharmaceuticals and Sunesis Pharmaceuticals. Previously, Dr. Adelman served as Vice President of Clinical Operations and Biometrics at Pharmacyclics, and as a Clinical Scientist at Genentech, where he was involved in the early development of omalizumab and bevacizumab. Dr. Adelman has also led the development of other therapies for celiac disease and food allergy. Dr. Adelman began his career as an Assistant Professor of Clinical Medicine in the Division of Allergy and Immunology at the University of California, San Francisco, School of Medicine, where he was also Director of Clinical Allergy and Immunology. He has also served on the editorial boards of the Journal of Clinical Immunology and Clinical Immunology and as a clinical advisor to multiple biopharmaceutical companies. Dr. Adelman holds a bachelor's degree in biology from the University of California, Berkeley, and earned his M.D. from the University of California, Davis. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU and CIndU. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU and CIndU; the potential effects of the corporation reorganization and other cost cutting measures, including on Jasper's cash runway and any anticipated benefits thereof; Jasper's focus of its resources on the development of briquilimab in chronic urticaria, including halting its other clinical and preclinical programs; Jasper's intent to streamline its operations; Jasper's commitment to the development of briquilimab; and the expected timing of announcing additional data from the BEACON and open label studies. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper may be unable to raise capital to continue its operations and continue the BEACON study; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@ Allaire (investors)LifeSci Advisors617-435-6602jallaire@ Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
11-07-2025
- Business
- Globe and Mail
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Jasper Therapeutics, Inc. ('Jasper' or 'the Company') (NASDAQ: JSPR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Jasper reported 'updated data from Company's BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU and providing an update on the program," on July 7, 2025. According to the Company, "results from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question. The Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks." Based on this news, shares of Jasper fell by 55% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
04-07-2025
- Health
- Globe and Mail
Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Chronic Urticaria Pipeline Insight, 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Urticaria Pipeline Outlook Key Takeaways from the Chronic Urticaria Pipeline Report In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable. DelveInsight's Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment. The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others. Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs Chronic Urticaria Emerging Drugs Profile CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria. Povorcitinib - Incyte Corporation Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria. Briquilimab: Jasper Therapeutics Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria. The Chronic Urticaria Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment. Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight's detailed report now! @ New Chronic Urticaria Drugs Chronic Urticaria Companies Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Chronic Urticaria Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers Scope of the Chronic Urticaria Pipeline Report Coverage- Global Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others. Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others. Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Chronic Urticaria: Overview Pipeline Therapeutics Therapeutic Assessment Chronic Urticaria – DelveInsight's Analytical Perspective Late Stage Products (Phase III) CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd Mid Stage Products (Phase II) Povorcitinib - Incyte Corporation Early Stage Products (Phase I) Briquilimab: Jasper Therapeutics Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Chronic Urticaria Key Companies Chronic Urticaria Key Products Chronic Urticaria - Unmet Needs Chronic Urticaria - Market Drivers and Barriers Chronic Urticaria - Future Perspectives and Conclusion Chronic Urticaria Analyst Views Chronic Urticaria Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
